$Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: A study of the Eastern Cooperative Oncology Group (ECOG), E5995$

Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: A study of the Eastern Cooperative Oncology Group (ECOG), E5995

2-Chlorodeoxyadenosine (2-CdA) is a purine analog which has anti-leukemic activity in phase II trials in pediatric acute myeloid leukemia (AML) patients. An adult phase I trial suggested possible similar activity although neurotoxicity at higher doses was seen. We conducted a phase II trial of 2-CdA...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia research 2000-10, Vol.24 (10), p.871-875
Hauptverfasser:	Gordon, Michael S, Young, Molly L, Tallman, Martin S, Cripe, Larry D, Bennett, John M, Paietta, Elisabeth, Longo, Walter, Gerad, Henry, Mazza, Joseph, Rowe, Jacob M
Format:	Artikel
Sprache:	eng
Schlagworte:	2-Chlorodeoxyadenosine Acute myeloid leukemia Adult Aged Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Chemotherapy Cladribine - adverse effects Cladribine - therapeutic use Female Humans Leukemia, Myeloid, Acute - drug therapy Male Medical sciences Middle Aged Pharmacology. Drug treatments Purine analog Recurrence Salvage therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!